Clinical Trial Update: Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness [Phase 4]

View source ↗

Summary

A Phase 4 safety evaluation of subcutaneous methylnaltrexone for opioid-induced constipation in patients with advanced illness has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• RELISTOR (methylnaltrexone)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Opioid-Induced Constipation | Phase 4 | Status: COMPLETED | Results posted: 2018-03-07